ENTITY

Oryzon Genomics (ORY SM)

71
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
bullishOryzon Genomics
05 Jun 2024 07:10Issuer-paid

Oryzon Genomics - ALICE data published in The Lancet Haematology

Oryzon Genomics has announced the publication of the final ALICE trial results in the recognised peer-reviewed journal The Lancet Haematology. The...

Share
bullishOryzon Genomics
30 May 2024 19:10Issuer-paid

Oryzon Genomics - EC taps Oryzon for healthcare initiative

The European Commission has selected Oryzon to support a new healthcare initiative furthering innovation in the region. As an associated partner of...

Share
bullishOryzon Genomics
09 May 2024 01:10Issuer-paid

Oryzon Genomics - Doubling down on clinical activity in 2024

Oryzon’s Q124 results emphasised the company’s focus on advancing and expanding its CNS and oncology pipelines, driven by its core assets,...

Share
bullishOryzon Genomics
10 Apr 2024 01:10Issuer-paid

Oryzon Genomics - FDA green light for SCLC combination trial

With the FDA investigational new drug (IND) application clearance, Oryzon can commence its Phase I/II cooperative research and development...

Share
bullishOryzon Genomics
05 Apr 2024 19:10Issuer-paid

Oryzon Genomics - Third time is a charm; INNOVATIVE SME Seal

For the third consecutive time, Oryzon Genomics has received the INNOVATIVE SME Seal from the Spanish Ministry of Science and Innovation. This...

Share
x